Evidence map›Paper›PMID 23835049›Full record

ReviewCurrent opinion in virology2013

Impact of host and virus genome variability on HCV replication and response to interferon.

Cameron J Schweitzer, T Jake Liang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Cameron J SchweitzerLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD, USA. Electronic address: cameron.schweitzer@NIH.gov.
T Jake Liang

Funding

Molecular Approaches To Vaccine Development For Hepatitis CZIADK054503 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$18.9M
Therapy, Vaccine and Model Development in Viral Hepatitis and Liver DiseasesZIADK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2025
$17.5M
Studies of HCV Infection, Vaccine Development and HCV-Host interactionsZIADK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2022
$12.0M
MOLECULAR MECHANISMS OF CHOLESTEROL ABSORPTIONP01DK054504 · NIDDK · UNIVERSITY OF CINCINNATI · PI HUI, DAVID Y · 1999 to 2003
$4.0M
The Genetics of Disease Progression and Treatment Response in Hepatitis CZIADK054511 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2009 to 2017
$3.8M
NS5A GENE PRODUCT &MECHANISM OF HEPATITIS C VIRUS INTERFERON RESISTANCEZ01DK054505 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0M
TRANSGENIC MOUSE MODEL FOR STUDY OF VIRAL HEPATITIS CZ01DK054504 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 1997 to 2008
$1.0M
The Genetics of Disease Progression and Treatment Response in Hepatitis CZ01DK054511 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI LIANG, T. JAKE · 2007 to 2008
$927k
Intramural NIH HHS Z01 DK054504Intramural NIH HHS Z01 DK054505Intramural NIH HHS Z01 DK054511Intramural NIH HHS Z99 DA999999Intramural NIH HHS Z99 DK999999Intramural NIH HHS Z99 OD999999Intramural NIH HHS ZIA DK054504Intramural NIH HHS ZIA DK054505Intramural NIH HHS ZIA DK054511NIDDK NIH HHS P01 DK054504
6 · The paper itself

Abstract

Since the discovery of hepatitis C virus (HCV), treatment has proven difficult and the regimen of pegylated interferon-α and ribavirin is only effective for half of patients. Evidence suggests that host and viral genome variations play a role in either viral clearance or persistence. Powerful genomic technologies have made it possible to study genome-wide associations with treatment response, which yielded critical genetic polymorphisms that predict treatment response. This has important implications for treatment of HCV infection and opened the door to the possibility of genetic marker-guided treatment (personalized medicine). This review will focus on the recent advances in understanding host and viral genetic variations with regards to treatment and the importance for future therapeutic intervention.

Indexed as

AnimalsAntiviral AgentsGenetic VariationGenome, ViralHepacivirusHepatitis CHumansInterferon-alphaTreatment OutcomeVirus ReplicationAntiviral AgentsInterferon-alpha

Identifiers

PMID23835049
PMCPMC3797205

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.